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After the discovery of Toll-like receptors (TLR) in the late 1990s,
initial investigations were focused on understanding their role,
stimulating immune responses against infectious agents. Yet, the
human body is home to a myriad of TLR agonistic bacteria
that have not only established symbiosis with the immune sys-
tem but also likely contribute to the induction and maintenance
of immune homeostasis by dampening immune responses. In
fact, stimulation of TLRs might be critically involved in this
process and ultimately contribute to preventing development of
inflammatory and autoimmune diseases. Sander De Kivit and col-
leagues present an overview of those aspects, notably outlining
the role of gut epithelial TLRs in the induction of immunity
and the maintenance of tolerance (1). In addition, the authors
highlight the mechanisms through which the gut microbiota
regulates intestinal immune responses through interaction with
TLRs. The capacity of probiotic microorganisms to modulate
immunity via specific TLRs is further discussed in two arti-
cles by Julio Villena and Haruki Kitazawa. The authors explore
the role of TLR interaction with immunobiotics for the regula-
tion of intestinal inflammation in pigs, with a focus on TLR4
and Lactobacillus jensenii TL2937 (2). Interaction of probiotics
with TLR3 to promote beneficial immunity beyond the gut in
the respiratory tract is also examined (3). Specifically, inflam-
matory and immunoregulatory mechanisms conferred by Lac-
tobacillus rhamnosus CRL1505 are presented along with their
proposed effects increasing resistance to RSV infection while
limiting immunopathology.
While TLRs stimulate and regulate immunity against infec-
tious agents, they are also highly pursued targets for therapy of
cancer due to their strong ability to activate multiple arms of
the immune system, and in particular to stimulate those specific
cellular and cytokine responses critical to anti-tumor immunity.
However, the immune potentiating,anti-tumor effects of TLR ago-
nists may be restrained by their parallel ability to trigger immune
regulation. Dampening of immune responses may enable control
of inflammatory damage or immunopathology, but the downside
is a limiting effect on efficacy. The impact of this dichotomy on
the use of TLR agonists for immunotherapy of cancer is discussed
by Hailing Lu in a review article where key immune regulatory
facets of TLR agonists are presented, which may impair their effi-
cacy (4). The dual role of TLRs in cancer likely extends beyond the
dichotomy between immune stimulation and regulation. Inflam-
matory processes triggered by TLR engagement may notably con-
stitute a double-edged sword in elimination vs. development of
tumors. In that regard, Erin Burns and Nabiha Yusuf contribute
two opinion articles discussing TLR targeting for the treatment
of cancer. The use of TLR agonists for skin cancer treatment is
presented in the context of their impact on skin carcinogenesis,
and the question of TLR tolerance is also discussed (5). Similarly,
the dual effect of TLR agonists in breast cancer is examined, where
TLR stimulation might beneficially activate the immune system
but inflammatory processes may also promote tumor develop-
ment, while TLR-conferred immune regulation may further curb
anti-tumor immunity (6).
The mechanisms that underlie the immune regulatory proper-
ties of TLRs are not well understood. It is possible that the“default”
response induced by TLR stimulation may vary between cell
types, or depending on the microenvironment/anatomical loca-
tion of TLR-expressing cells (as exemplified in gut mucosal tissue).
Alexandra Zanin-Zhorov and colleagues described an immune
regulatory mechanism conferred by TLR expression on T cells,
which the authors review herein and discuss in the context of TLR-
induced T cell effector functions (7). The role played by endoge-
nous TLR ligands in conferring immune regulatory mechanisms
is also presented. Nobuhiro Nakamoto and Takanori Kanai focus
on a key organ, the liver, where various types of TLR-expressing
cells are faced with continuous exposure to foreign antigens (8).
The authors review immune stimulatory and regulatory effects of
TLR signaling that coexist in the liver and influence liver health
and disease. Elke Gülden and Li Wen concentrate on another
organ, the pancreas, where TLR engagement also ultimately con-
trols health and disease (9). Here, the beneficial and detrimental
effects of TLR stimulation on type-1 diabetes are discussed, and
notably the authors explore how endogenous TLR agonists can
confer immune activation vs. regulation of autoreactive T cells.
To close on the question of immune regulation conferred by
TLRs, Himanshu Singh Chandel and colleagues contribute an
opinion article investigating an alternative immune modulatory
aspect that may influence the outcome of parasitic infection (10).
The authors review mechanisms that underlie cross-talk between
TLRs and CD40, and discuss how this interaction may determine
the nature of anti-leishmanial immune responses and ultimately
parasite elimination.
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